ANKRD22
- Known as:
- ANKRD22
- Catalog number:
- 001620A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- ANKRD22
Related genes to: ANKRD22
- Gene:
- ANKRD22 NIH gene
- Name:
- ankyrin repeat domain 22
- Previous symbol:
- -
- Synonyms:
- MGC22805
- Chromosome:
- 10q23.31
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-27
- Date modifiied:
- 2017-07-14
Related products to: ANKRD22
Related articles to: ANKRD22
- Antiphospholipid syndrome (APS) lacks disease-modifying targeted therapies, and its molecular heterogeneity remains poorly characterized. We employed an integrative systems pharmacology approach combining weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, Connectivity Map (CMap) screening, and molecular docking to prioritize candidate therapeutic targets in APS. WGCNA of purified-neutrophil bulk RNA-seq (n = 18), with module preservation confirmed in whole blood (n = 88), identified two disease-associated modules: ME10 (176 genes, r = 0.77, interferon-I signaling) and ME2 (3409 genes, r = 0.79, degranulation/innate activation). Single-cell analysis of 26,936 B cells revealed transitional B cells with elevated ME2 scores and aberrant SPI1 expression, suggesting myeloid-like transcriptional reprogramming. CMap analysis ranked chloroquine - a 4-aminoquinoline antimalarial closely related to hydroxychloroquine, which is recommended as adjunctive therapy in APS - among top ME2 candidates (NCS = -2.07), supporting the biological relevance of the screen. DrugBank mapping identified 14 FDA-approved drugs targeting module genes, and a 3-gene machine learning signature (CORO1A, ANKRD22, IFITM1) achieved cross-tissue validation AUC of 0.802. External datasets supported ME2 pathway modulation by NAPc2 intervention and cross-tissue module conservation in platelets. Patient-level ME10 x ME2 stratification revealed four molecular subtypes with distinct pathway activation profiles. This framework prioritizes candidate targets across both IFN-I and degranulation pathways, generating hypotheses for pathway-guided therapeutic development that require experimental and clinical validation. - Source: PubMed
Publication date: 2026/08/26
Sun BinLu YiqiaoLiu WeiWang Chengze - Blood-based biomarkers discovered by machine learning often lack disease specificity and cross-population robustness for clinical applications. We describe a biomarker discovery strategy that exploits monocytes as circulating sentinels to amplify disease-perturbed signals in blood. This strategy leverages monocyteMINER, a mechanistic transcriptional regulatory network inferred from monocyte transcriptomes of 1,202 healthy individuals. As proof-of-concept, we uncovered a 31-gene atherosclerosis-perturbed network that underpins disease etiology, identifying diagnostic signatures for coronary artery disease (ARAP2, P2RY14, FKBP15) and acute myocardial infarction (SERPINA1, ASGR2). For tuberculosis (TB), monocyteMINER uncovered a 5-gene signature (MAS_TB_META5: ANKRD22, AIM2, VAMP5, GBP5, TGM2) from just 438 samples. MAS_TB_META5 outperformed 77 existing signatures across 18 cohorts (>4,400 patients, 12 countries), achieving WHO target product profile for high-sensitivity screening (including in advanced HIV patients), and predicting TB progression up to 5 years before diagnosis. Thus, our findings show that monocyteMINER offers a generalizable platform for discovering clinically actionable biomarkers for diverse diseases. - Source: PubMed
Publication date: 2026/07/06
Arrieta-Ortiz Mario LWu Wei-JuBaliga Nitin S - ANKRD22 is a protein involved in tumor immune regulation. To elucidate its role in ovarian cancer, we analyzed its expression pattern and association with the tumor immune microenvironment. Bioinformatics analyses revealed upregulation of ANKRD22 in ovarian cancer tissues compared with normal controls. High ANKRD22 expression correlated with favorable patient prognosis, suggesting its potential as a prognostic biomarker. In vitro experiments using the ID8 murine ovarian cancer cell line, selected for its relevance to immunocompetent mouse models in tumor microenvironment studies, revealed that ANKRD22 expression is regulated by the tumor microenvironment. Monocytic myeloid-derived suppressor cells (M-MDSCs) with Ankrd22 knockout exhibited enhanced immunosuppressive function, inhibited T lymphocyte proliferation and reduced IL-2 secretion. These M-MDSCs promoted ovarian cancer cell proliferation primarily through direct contact. RNA sequencing suggested that Ankrd22 might regulate the immunosuppressive function of M-MDSCs by modulating fatty acid metabolism. In vivo rescue experiments in a subcutaneous tumor model confirmed that Ankrd22 mediates the protumor effect of M-MDSCs. In summary, this study demonstrated that downregulation of ANKRD22 promotes ovarian cancer progression by enhancing the immunosuppressive function of M-MDSCs, providing a theoretical basis for targeting ANKRD22 in ovarian cancer treatment. - Source: PubMed
Publication date: 2026/06/30
Chen HuanhuanPan TianhuiHe QionghuaLi Shu YuFei JingZhou JianweiZhong Dandan - SERPING1, which encodes the C1 inhibitor (C1-INH) of the complement system, and plays a key regulator in regulating inflammatory responses and immune homeostasis. SERPING1 is downregulated in various disease, this downregulation occurs through the body's negative feedback resulting from the overactivation of the complement system in diseases such as infections and acute inflammatory responses. Additionally, SERPING1 is vital for tumor immunomodulation. Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive type of non-Hodgkin lymphoma. More treatment options are becoming available for this disease. However, some patients still experience recurrence or even disease progression during treatment. Consequently, elucidating the molecular underpinnings of DLBCL's malignant behavior and identifying novel prognostic markers and therapeutic targets are paramount for improving patient outcomes. - Source: PubMed
Publication date: 2026/06/03
Wang JinhuiLi ZhihuiZhan XinrongZhang YanpingWang ZhongliangXing PengtaoLiu MengmengGuo MengyiXu KailiWang Haoyan - Rheumatoid arthritis (RA) is a chronic autoimmune disease that can lead to multiple complications. Sjögren's syndrome (SS) is another autoimmune condition that may occur as a primary disorder or in conjunction with other autoimmune diseases, including RA. This study aimed to investigate the shared gene signatures between RA and SS. Gene expression datasets for RA (GSE15573, GSE93776) and SS (GSE48378, GSE94510, GSE93683) were obtained and analyzed to identify differentially expressed genes (DEGs) in peripheral blood mononuclear cells (PBMCs) and T cells. Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the DEGs identified. Quantitative real-time PCR (qRT-PCR) was used to validate the expression levels of DEGs in PBMCs from patients with RA and SS. A total of 244 DEGs were identified from the RA PBMC dataset, comprising 142 upregulated genes and 102 downregulated genes. These DEGs were significantly enriched in biological processes related to immune responses, including cellular response to lipopolysaccharide, defense response against fungi, inflammatory responses, and antibacterial humoral responses. In contrast, 335 DEGs were identified from the SS PBMC dataset; among these, 320 genes were upregulated, while 15 were downregulated. The DEGs associated with SS showed strong involvement in defense responses against viruses, innate immune responses, viral responses, as well as cellular reactions to lipopolysaccharide. Moreover, we identified 12 shared DEGs between RA and SS PBMCs: RNASE2, NDUFB3, LY96, ANKRD22, EIF2AK2, RNASE3, CLEC4D, TNFAIP6, DYNLT1, RPS27L, LILRA5, and F5. Validation through qRT-PCR confirmed increased expression levels of RNASE2, RNASE3, NDUFB3, and EIF2AK2 in PBMCs. This study successfully delineated key DEGs along with their associated biological processes within the context of RA and SS PBMCs. Through bioinformatics analyses combined with qRT-PCR validation, we have identified four critical genes that may serve as potential biomarkers or therapeutic targets for further investigation. - Source: PubMed
Publication date: 2026/04/25
Li Yi-FanGao Zhao-WeiLiu LiWang XiFan KunLin FangHei Ruo-Xuan